Biopool Wins Approvals From Regulatory Agency

Biopool International in Ventura has received approval from the French regulatory agency L’Agence du Medicament to market 11 of its products.

Michael D. Bick, chairman and chief executive officer of Biopool, said the company hopes to establish Biopool’s market presence in key European countries.

In conjunction with these efforts, Biopool has registered a local sales office in France and will increase sales activities as additional product market approvals are received from the government.

“While we currently derive some 23% of our total sales revenues from Europe, we have yet to establish what could be considered a significant presence in any European country,” Bick said. “We are first focusing on building our business in France because it is the second-largest market by population and the largest market for per capita spending on immunohematology products within the European Union.”

Biopool develops test kits to diagnose blood disorders and monitor the presence of drugs of abuse, plus products used to screen for antibodies and type whole blood. The company’s line of more than 150 FDA-approved products is sold to hospitals, blood banks, and clinical and reference laboratories.